Clinical trials: Lung Function
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study was to assess the effect of CK-2127107 relative to placebo on cycle ergometer exercise tolerance, assessed as change from period baseline in constant work rate (CWR) endurance time, utilizing a…
- Trial name
- NCT02662582
- Testing
- Reldesemtiv
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Obstructive Sleep Apnea
A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea
This study is conducted to investigate the effects of ACT-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea
- Trial name
- NCT03765294
- Testing
- ACT-541468
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Cystic Fibrosis
SD Cystic Fibrosis Study
Subject with Cystic Fibrosis have increased clearance of many drugs. Based on pre-clinical data SB656933 was found to have low clearance and high bio-availability.
- Trial name
- NCT00605761
- Testing
- SB656933
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Malnutrition, Pulmonary Disease, Chronic Obstructive
Nutritional Supplementation in Adults With Chronic Respiratory Disease
The purpose of this study is to determine whether nutritional support with a complete formula is effective to improve malnutrition and respiratory function in patients with chronic pulmonary disease compared to the standard…
- Conditions
- Malnutrition, Pulmonary Disease, Chronic Obstructive, Other Pulmonary Disease, Chronic Obstructive
- Trial name
- OFOS (NCT02102009)
- Testing
- Complete enteral formula, Dietary Advise
- Where
- Peru
- Volunteers
- 99 people
- Sponsor
- Laboratorios Ordesa
Pulmonary Disease, Chronic Obstructive
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/UMEC/VI [100/62.5/25 microgram (mcg)]…
- Trial name
- NCT03478683
- Testing
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 729 people
- Sponsor
- GlaxoSmithKline
Asthma
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\xa0The purpose of this study is to assess how depemokimab, a…
- Trial name
- NCT06979323
- Testing
- Depemokimab
- Where
- 50 sites in United States, Belgium and 10 more
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Advanced Cancer, Ovarian Cancer
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced…
- Conditions
- Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT04354246
- Testing
- Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy.
- Where
- 9 sites in United States
- Volunteers
- 94 people
- Sponsor
- Compugen Ltd
Asthma
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years…
- Trial name
- MITCHELL (NCT06644924)
- Testing
- Intervention: AS MDI, Intervention: Ventolin Evohaler
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
RELOVAIR® Lung Deflation Study
The primary objective of the study is to test the hypothesis that lung hyperinflation contributes to cardiac dysfunction in COPD and that the treatment of lung deflation with FF/VI Inhalation Powder 100/25 mcg administered once…
- Trial name
- NCT01691885
- Testing
- Fluticasone Furoate, Vilanterol
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Limb-girdle Muscular Dystrophy
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy…
- Trial name
- NCT04475926
- Where
- 26 sites in United States, Belgium and 8 more
- Volunteers
- 205 people
- Sponsor
- Sarepta Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis
NAL ER IPF Respiratory Function and Safety Study
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
- Trial name
- NCT07036029
- Testing
- NAL ER
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Trevi Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
- Trial name
- CRESCENDO (NCT05492877)
- Testing
- Mitiperstat (AZD4831)
- Where
- 101 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- AstraZeneca
Asthma in Children
Proof-of-concept of the Measurement of Lung Function Using the Relaxed Expiratory Occlusion Monitor (REOM)
(i) To validate the inversed occlusion technique by comparing the results of resistance obtained on the relaxed expiratory occlusion monitor (REOM) with the resistance obtained with respiratory oscillometry (OSC) measurements on…
- Trial name
- NCT04903145
- Testing
- REOM
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Thorasys Thoracic Medical Systems Inc.
Asthma
Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)
Primary objective: To investigate the safety and local tolerability of increasing cumulative doses (2, 4, 6 actuations) of a low (0.1%) and a high (0.5%) concentration of BHT administered via oral inhalation with the Respimat®…
- Trial name
- NCT02220673
- Testing
- BHT 0.1%, BHT 0.5%
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Preeclampsia, Hypertension
Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers
Preeclampsia (Pre-E) is a hypertensive disease of pregnancy with multi-system involvement that usually occurs in the second half of pregnancy. Pre-E occurs in 5% to 7% of U.S. pregnancies, and is the third-leading cause of U.S.
- Conditions
- Preeclampsia, Hypertension, Proteinuria, Thrombocytopenia
- Trial name
- NCT02780414
- Where
- 20 sites in United States
- Volunteers
- 1,730 people
- Sponsor
- Progenity, Inc.
Pulmonary Disease, Chronic Obstructive
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323621
- Testing
- Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Salbutamol as needed
- Where
- 51 sites in United States, Germany and 4 more
- Volunteers
- 512 people
- Sponsor
- GlaxoSmithKline
Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
- Trial name
- CHINOOK (NCT03953300)
- Testing
- Benralizumab
- Where
- 35 sites in United States, Canada and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
OTIVACTO Spain Non Interventional Study
This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC.
- Trial name
- NCT02927795
- Where
- 79 sites in Spain
- Volunteers
- 257 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This will be a Phase IIIb multicentre, randomized, double-blind, double-dummy, 12-week parallel group study evaluating the effects of once daily in the morning treatment of FF/VI Inhalation Powder versus Fluticasone…
- Trial name
- NCT01706328
- Testing
- FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
- Where
- 63 sites in United States, Germany and 3 more
- Volunteers
- 828 people
- Sponsor
- GlaxoSmithKline
Malignant Pain, Non-malignant Pain
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.
- Trial name
- NCT02321397
- Testing
- Oxycodone, Naloxone
- Where
- Germany
- Volunteers
- 155 people
- Sponsor
- Mundipharma Research GmbH & Co KG